.ANALYSIS HIGHLIGHT.16 Oct 2024.
In the NIAGARA trial, the add-on of perioperative durvalumab to standard procedure for muscle-invasive sac cancer cells boosted event-free and overall survival, noting a brand-new therapy option for this problem.